2022 Revenues ($USD) : $535,031,000
2022 R&D spend : $201,303,000
2022 Number of Employees : 1,167
Fiscal Year End : 12/31/2021
Company CEO : Asaf Danziger, CEO

Root, Switzerland–based Novocure is an oncology company specializing in developing therapies for solid tumors. The company's tumor treating fields technology is FDA-approved for recurrent and newly-diagnosed glioblastoma and mesothelioma. In June, the company announced that a Phase 2 pilot trial investigating the use of tumor treating fields with standard-of-care chemotherapy met its primary endpoint for first-line treatment of gastric cancer. The company is also performing clinical trials testing the potential of the technology for non-small cell lung cancer, ovarian cancer, and pancreatic cancer, among others. In addition to its home base in Switzerland, the company has regional operating centers in Portsmouth, New Hampshire and Tokyo, and a research center in Haifa, Israel.  –BB